Prodrug activation by Cryptosporidium thymidine kinase.
Cryptosporidium spp. cause acute gastrointestinal disease that can be fatal for immunocompromised individuals. These protozoan parasites are resistant to conventional antiparasitic chemotherapies and the currently available drugs to treat these infections are largely ineffective. Genomic studies suggest that, unlike other protozoan parasites, Cryptosporidium is incapable of de novo pyrimidine biosynthesis. Curiously, these parasites possess redundant pathways to produce dTMP, one involving thymidine kinase (TK) and the second via thymidylate synthase-dihydrofolate reductase. Here we report the expression and characterization of TK from C. parvum. Unlike other TKs, CpTK is a stable trimer in the presence and absence of substrates and the activator dCTP. Whereas the values of k(cat) = 0.28 s(-1) and K(m)(,ATP) = 140 microm are similar to those of human TK1, the value of K(m)(thymidine) = 48 microm is 100-fold greater, reflecting the abundance of thymidine in the gastrointestinal tract. Surprisingly, the antiparasitic nucleosides AraT, AraC, and IDC are not substrates for CpTK, indicating that Cryptosporidium possesses another deoxynucleoside kinase. Trifluoromethyl thymidine and 5-fluorodeoxyuridine are good substrates for CpTK, and both compounds inhibit parasite growth in an in vitro model of C. parvum infection. Trifluorothymidine is also effective in a mouse model of acute disease. These observations suggest that CpTK-activated pro-drugs may be an effective strategy for treating cryptosporidiosis.
Sun
Xin E
XE
Brandeis University, Waltham, Massachusetts 02454, USA.
Sharling
Lisa
L
Muthalagi
Mani
M
Mudeppa
Devaraja G
DG
Pankiewicz
Krzysztof W
KW
Felczak
Krzysztof
K
Rathod
Pradipsinh K
PK
Mead
Jan
J
Striepen
Boris
B
Hedstrom
Lizbeth
L
D000818:Animals; D000981:Antiprotozoal Agents / Q000494:pharmacology*; D045744:Cell Line, Tumor; D003457:Cryptosporidiosis / Q000188:drug therapy* / Q000201:enzymology; D016785:Cryptosporidium parvum / Q000201:enzymology* / Q000235:genetics; D004195:Disease Models, Animal; D005467:Floxuridine / Q000494:pharmacology; D018503:Genome, Protozoan; D006801:Humans; D051379:Mice; D018345:Mice, Knockout; D011355:Prodrugs / Q000494:pharmacology*; D015800:Protozoan Proteins / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D011743:Pyrimidines / Q000378:metabolism / Q000494:pharmacology; D011994:Recombinant Proteins / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D013937:Thymidine Kinase / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism
D000981:Antiprotozoal Agents; D011355:Prodrugs; D015800:Protozoan Proteins; D011743:Pyrimidines; D011994:Recombinant Proteins; D005467:Floxuridine; D013937:Thymidine Kinase; C030986:pyrimidine